A court ruling has saddled biodefense specialist Siga Technologies ($SIGA) with debts it cannot pay, the company said, and the biotech is filing for bankruptcy in an effort to keep its doors open long enough for an appeal. The issue revolves around Tecovirimat, an investigational smallpox treatment Siga provides to the U.S. under contract. Back in 2006, PharmAthene ($PIP) filed suit over Tecovirimat, claiming a share of the drug's proceeds, and, last month, a federal court found in its favor, ordering Siga to hand over as-yet-undecided damages in a lump sum. That figure is likely to be substantial, Siga said, so the company is fleeing for the protection of bankruptcy to stop PharmAthene from taking any enforcement action. In the meantime, the company is gearing up to mount an appeal, and CEO Eric Rose said Siga has enough cash to keep things moving until it can get back in court. More